Gilead Sciences, Inc. (GILD) Analysts See $2.07 EPS; Fate Therapeutics (FATE) Covered By 8 Bullish Analysts Last Week

October 13, 2017 - By Adrian Mccoy

Analysts expect Gilead Sciences, Inc. (NASDAQ:GILD) to report $2.07 EPS on November, 7.They anticipate $0.63 EPS change or 23.33% from last quarter’s $2.7 EPS. GILD’s profit would be $2.71 billion giving it 9.79 P/E if the $2.07 EPS is correct. After having $2.51 EPS previously, Gilead Sciences, Inc.’s analysts see -17.53% EPS growth. About 5.64 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since October 13, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

Among 8 analysts covering Fate Therapeutics (NASDAQ:FATE), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fate Therapeutics had 8 analyst reports since October 6, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. The rating was initiated by Leerink Swann with “Buy” on Friday, September 8. The stock of Fate Therapeutics Inc (NASDAQ:FATE) earned “Buy” rating by H.C. Wainwright on Thursday, October 12. As per Tuesday, October 6, the company rating was initiated by Raymond James. TH Capital initiated Fate Therapeutics Inc (NASDAQ:FATE) rating on Thursday, September 22. TH Capital has “Buy” rating and $8 target. Wedbush maintained the stock with “Outperform” rating in Tuesday, November 8 report. The firm earned “Buy” rating on Thursday, September 22 by Roth Capital. BMO Capital Markets initiated the shares of FATE in report on Tuesday, April 12 with “Outperform” rating. See Fate Therapeutics Inc (NASDAQ:FATE) latest ratings:

12/10/2017 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $7 Reinitiate
08/09/2017 Broker: Leerink Swann Rating: Buy New Target: $7.0 Initiate

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $167.73 million. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. It currently has negative earnings. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

The stock decreased 0.49% or $0.02 on October 13, reaching $4.05. About 504,409 shares traded or 103.62% up from the average. Fate Therapeutics Inc (NASDAQ:FATE) has risen 166.12% since October 13, 2016 and is uptrending. It has outperformed by 149.42% the S&P500.

Investors sentiment decreased to 1.43 in Q2 2017. Its down 4.97, from 6.4 in 2017Q1. It dived, as 11 investors sold Fate Therapeutics Inc shares while 12 reduced holdings. 19 funds opened positions while 14 raised stakes. 25.76 million shares or 48.07% less from 49.60 million shares in 2017Q1 were reported. Dimensional Fund L P invested in 23,500 shares. 800 are held by Tci Wealth Advisors. Nationwide Fund Advsrs stated it has 21,117 shares. Morgan Stanley reported 633,944 shares. State Street Corporation stated it has 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE). Vigilant Mngmt Ltd Liability Corporation stated it has 1,000 shares or 0% of all its holdings. Tiaa Cref Investment Ltd accumulated 115,275 shares. Kingdon Management Lc holds 0.25% or 1.15M shares in its portfolio. Fmr Lc owns 4.35 million shares. Franklin Res invested in 0.01% or 6.08M shares. 50,004 were reported by Jacobs Levy Equity Mngmt. Northern Tru Corporation reported 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE). Bnp Paribas Arbitrage Sa invested 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE). Barclays Public Ltd Liability Corp holds 11,668 shares or 0% of its portfolio. Geode Cap Ltd owns 177,082 shares.

Gilead Sciences, Inc. is a research biopharmaceutical firm that discovers, develops and commercializes medicines in areas of unmet medical need. The company has market cap of $106.00 billion. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome , liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. It has a 8.81 P/E ratio. The Company’s products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 18 have Buy rating, 0 Sell and 12 Hold. Therefore 60% are positive. Gilead Sciences had 98 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer on Wednesday, February 3 with “Outperform”. Credit Suisse maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Monday, August 28. Credit Suisse has “Buy” rating and $79.0 target. RBC Capital Markets maintained the stock with “Buy” rating in Wednesday, October 4 report. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Neutral” rating by Citigroup on Wednesday, February 8. The company was maintained on Wednesday, February 3 by RBC Capital Markets. As per Tuesday, May 30, the company rating was maintained by Cowen & Co. William Blair initiated Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, August 31 with “Buy” rating. The stock has “Neutral” rating by Bank of America on Friday, January 15. Mizuho maintained the shares of GILD in report on Thursday, September 28 with “Buy” rating. The firm has “Buy” rating by Mizuho given on Tuesday, November 8.

Since May 1, 2017, it had 0 insider buys, and 5 selling transactions for $11.13 million activity. $325,114 worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Alton Gregg H. $4.78 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by MARTIN JOHN C. 9,943 shares were sold by Cogan John Francis, worth $668,667.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :